HLB테라퓨틱스 Stock: price and insider trades · South Korea

HLB테라퓨틱스 belongs to the Health Care sector. Filings by its managers are published through DART (FSS). 5 insiders have disclosed 15 filings since 18 October 2025.

The flow runs one way only: 4 insiders bought (13 purchases totalling €1.4M) and nobody sold on the market. The totals exclude 9 filings filed without an amount. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Among those who bought: 1 major shareholder and 1 board member. Biggest ticket of the year: €1.2M, bought by Hlb and made public on 17 March 2026 (1.0% of market cap).

Compared with its exchange (2,648 companies, median 7 filings), a count of 15 filings is above the norm. Over the whole record (from 2021), the tally stands at 51 purchases and 1 sale.

In all, 2 purchases were made within 30 days of a purchase by another insider of the company. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase. The clock since the last published purchase (4 September 2026) now reads 44 days. The median gap between a trade and its publication by DART (FSS) is 5 days. Until a filing is published, the market cannot know about the trade.

In the same sector, recent insider purchases at Anixa Biosciences Inc and Vivos Inc also feature in our signals. Every figure here comes from the filings published by DART (FSS) and describes the past, not future prices; it is not investment advice.